Bayer, Versant back a $250M cell therapy startup on a quest to create off-the-shelf immuno-oncology therapies
Look out Fate Therapeutics — Versant Ventures’ Century Therapeutics is lurking in the burgeoning field of off-the-shelf cell therapeutics that offer the promise of quicker, cheaper and potent cancer treatments. The Philadelphia-based biotech unveiled on Monday a meaty $250 million round of financing — led by Bayer’s venture arm — after Versant spawned it in 2018 to develop induced pluripotent stem cells (iPSC)-derived products to fight cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.